Dr. Stephen V. Liu
Claim this profileMedStar Georgetown University Hospital
Expert in Lung Cancer
Studies Non-Small Cell Lung Cancer
16 reported clinical trials
29 drugs studied
Area of expertise
1Lung Cancer
Global LeaderStage IV
Stage III
ALK positive
2Non-Small Cell Lung Cancer
Stage IV
EGFR positive
Stage III
Affiliated Hospitals
Clinical Trials Stephen V. Liu is currently running
Tazemetostat + Topotecan + Pembrolizumab
for Small Cell Lung Cancer
This phase I trial tests the safety, side effects, and best dose of tazemetostat in combination with topotecan and pembrolizumab in treating patients with small cell lung cancer that has come back after a period of improvement (recurrent). Tazemetostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Chemotherapy drugs, such as topotecan, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving tazemetostat in combination with topotecan and pembrolizumab may shrink or stabilize recurrent small cell lung cancer.
Recruiting1 award Phase 119 criteria
Disitamab Vedotin + Tucatinib
for Breast Cancer
This clinical trial is studying solid tumor cancers. A solid tumor is one that starts in part of your body like your lungs or liver instead of your blood. Once they've grown bigger in one spot or spread to other parts of the body, they're harder to treat. This is called advanced or metastatic cancer. Participants in this study must have breast cancer or gastric cancer. Participants must have tumors that have HER2 on them. This allows the cancer to grow more quickly or spread faster. There are few treatment options for patients with advanced or metastatic solid tumors that express HER2. This clinical trial uses an experimental drug called disitamab vedotin (DV). Disitamab vedotin is a type of antibody drug conjugate or ADC. ADCs are designed to stick to cancer cells and kill them. This clinical trial uses a drug called tucatinib, which has been approved to treat cancer in the United States and some other countries. This drug is sold under the brand name TUKYSA®. This study will test how safe and how well DV with tucatinib works for participants with solid tumors. This study will also test what side effects happen when participants take these drugs. A side effect is anything a drug does to the body besides treating the disease.
Recruiting1 award Phase 26 criteria
More about Stephen V. Liu
Clinical Trial Related8 years of experience running clinical trials · Led 16 trials as a Principal Investigator · 6 Active Clinical TrialsTreatments Stephen V. Liu has experience with
- Pembrolizumab
- Carboplatin
- Nivolumab
- Paclitaxel
- Pemetrexed
- Atezolizumab
Breakdown of trials Stephen V. Liu has run
Lung Cancer
Non-Small Cell Lung Cancer
Solid Tumors
Pancreatic Cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Stephen V. Liu specialize in?
Stephen V. Liu focuses on Lung Cancer and Non-Small Cell Lung Cancer. In particular, much of their work with Lung Cancer has involved Stage IV patients, or patients who are Stage III.
Is Stephen V. Liu currently recruiting for clinical trials?
Yes, Stephen V. Liu is currently recruiting for 6 clinical trials in Washington District of Columbia. If you're interested in participating, you should apply.
Are there any treatments that Stephen V. Liu has studied deeply?
Yes, Stephen V. Liu has studied treatments such as Pembrolizumab, Carboplatin, Nivolumab.
What is the best way to schedule an appointment with Stephen V. Liu?
Apply for one of the trials that Stephen V. Liu is conducting.
What is the office address of Stephen V. Liu?
The office of Stephen V. Liu is located at: MedStar Georgetown University Hospital, Washington, District of Columbia 20007 United States. This is the address for their practice at the MedStar Georgetown University Hospital.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.